Supportive Therapieansätze beim hepatozellulären Karzinom

Zurück zum Zitat Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen YH, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Dadduzio V, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK (2018) Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. J Clin Oncol 36:abstr 4019CrossRef Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen YH, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Dadduzio V, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK (2018) Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. J Clin Oncol 36:abstr 4019CrossRef

Zurück zum Zitat Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE Investigators (2017) Regorafenib for patients withhepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66CrossRefPubMed Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE Investigators (2017) Regorafenib for patients withhepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66CrossRefPubMed

Zurück zum Zitat Couto OF, Dvorchik I, Carr BI (2007) Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 52(11):3285–3289CrossRefPubMed Couto OF, Dvorchik I, Carr BI (2007) Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 52(11):3285–3289CrossRefPubMed

Zurück zum Zitat EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215-0 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215-0

Zurück zum Zitat Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F (2018) Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 67(5):1784–1796CrossRefPubMed Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F (2018) Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 67(5):1784–1796CrossRefPubMed

Zurück zum Zitat Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51(11):1269–1326CrossRefPubMed Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51(11):1269–1326CrossRefPubMed

Zurück zum Zitat Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173CrossRefPubMed Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173CrossRefPubMed

Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390CrossRefPubMed

Zurück zum Zitat Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, Rosi S, Gola E, Frigo AC, Stanco M, Destro C, Rupolo G, Mantoan D, Gatta A, Angeli P (2013) How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 59(2):257–264CrossRefPubMed Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, Rosi S, Gola E, Frigo AC, Stanco M, Destro C, Rupolo G, Mantoan D, Gatta A, Angeli P (2013) How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 59(2):257–264CrossRefPubMed

Zurück zum Zitat Ständer S, Zeidler C, Augustin M, Bayer G, Kremer AE, Legat FJ, Maisel P, Mettang T, Metz M, Nast A, Niemeier V, Raap U, Schneider G, Ständer HF, Staubach P, Streit M, Weisshaar E (2017) S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 15(8):860–873PubMed Ständer S, Zeidler C, Augustin M, Bayer G, Kremer AE, Legat FJ, Maisel P, Mettang T, Metz M, Nast A, Niemeier V, Raap U, Schneider G, Ständer HF, Staubach P, Streit M, Weisshaar E (2017) S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 15(8):860–873PubMed

Zurück zum Zitat Trojan J, Berg T, Buggisch P, Schott E, Tamm I, Welslau M, Vogel A (2017) Beste supportive Behandlung bei Patienten mit therapie-refraktärem, hepatozellulären Karzinom (HCC) – Ergebnisse einer Delphi-Studie. Z Gastroenterol 55(8):57–299 Trojan J, Berg T, Buggisch P, Schott E, Tamm I, Welslau M, Vogel A (2017) Beste supportive Behandlung bei Patienten mit therapie-refraktärem, hepatozellulären Karzinom (HCC) – Ergebnisse einer Delphi-Studie. Z Gastroenterol 55(8):57–299

Zurück zum Zitat Woodrell CD, Hansen L, Schiano TD, Goldstein NE (2018) Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults. Clin Ther 40(4):512–525CrossRefPubMed Woodrell CD, Hansen L, Schiano TD, Goldstein NE (2018) Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults. Clin Ther 40(4):512–525CrossRefPubMed

Zurück zum Zitat Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Kudo M (2018) REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 36(suppl; abstr 4003) Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Kudo M (2018) REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 36(suppl; abstr 4003)

Zurück zum Zitat Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA (2018) Determinants and outcomes of hospice utilization among patients with advance-staged hepatocellular carcinoma in a veteran affairs population. Dig Dis Sci 63(5):1173–1181CrossRefPubMed Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA (2018) Determinants and outcomes of hospice utilization among patients with advance-staged hepatocellular carcinoma in a veteran affairs population. Dig Dis Sci 63(5):1173–1181CrossRefPubMed